What Hugel Control does

Hugel Inc. is a South Korean bio-pharmaceutical company specializing in medical aesthetics products, principally botulinum toxin and dermal fillers. Founded in 2001 (firmographics) / 2009 (company history), the company is publicly traded on KOSDAQ under ticker 145020 and headquartered in South Korea with 501-1000 employees. Its flagship product, Letybo (letibotulinumtoxinA-wlbg), received FDA approval in 2024, making it only the 6th neuromodulator to receive FDA clearance in over 20 years and giving Hugel regulatory approvals in the three largest botulinum toxin markets (U.S., China, Europe). The product portfolio also includes dermal fillers, CellREDM (an ECM-based injectable for skin regeneration distributed through a partnership with Hans Biomed in South Korea), and BYRYZN BR, a premium dermocosmetics brand launched in China.

The company operates a hybrid go-to-market model combining distributor partnerships with direct sales. In the U.S., BENEV Company handles commercialization of Letybo; in South Korea, Hans Biomed distributes CellREDM. Hugel employs a multi-channel marketing approach centered on industry conferences (AMWC KOREA, J.P. Morgan Healthcare Conference), the L.E.A.D. education program featuring live demonstrations, and global networking events with healthcare professionals. Pricing is structured to be cost-competitive against incumbent Botox: Letybo launched in the U.S. at approximately USD 7 per unit versus Botox at ~USD 15 per unit.

FY2025 net sales reached KRW 425.1 billion (+14% YoY), with Q1 2026 net sales of KRW 116.6 billion (+29.9% YoY). The company has set a 2028 sales target of KRW 900 billion with over 30% from the U.S. market. Products are distributed across 65 countries with over 31 million successful treatments recorded globally. Leadership is headed by Carrie Strom as President and Global CEO.

Name

Hugel Control

Legal name

Hugel Inc.

Website

https://hugel.co.kr

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Hugel Inc. is a South Korean bio-pharmaceutical company that develops and commercializes medical aesthetics products, including FDA-approved botulinum toxin (Letybo), dermal fillers, ECM-based injectables (CellREDM), and dermocosmetics (BYRYZN BR), serving healthcare professionals and aesthetic clinics across 65 countries.

Ownership category

akta.pro rank

Product category

Medical Aesthetics Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Botulinum toxin products
• Dermal fillers
• Medical aesthetics
• Injectable treatments
• Cosmetic pharmaceuticals

Headquarters

HQ city

Chuncheon

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Marketing or Sales, Technology or R&D, Personnel

Revenue model

1. Botulinum Toxin Products: Primary revenue driver with botulinum toxin sales growing 60.6% year-on-year to KRW 65.4 billion in Q1 2026. Products include Letybo and Botuligin Capture EX Ampoule.
2. Dermal Fillers: Dermal filler products contributing to strong global demand alongside botulinum toxin products. Export share rising from 66% in 2024 to 74% in 2025.
3. ECM-based Injectables: CellREDM distributed through partnership with Hans Biomed, expanding portfolio into skin regeneration treatments.
4. Dermocosmetics (BYRYZN BR): Premium dermocosmetics brand launched in China, starting with Botuligin Capture EX Ampoule, with plans to introduce four more products under the line.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels4 records

Core offering

Hugel Inc. develops, manufactures, and commercializes medical aesthetics products including FDA-approved botulinum toxin (Letybo/letibotulinumtoxinA), dermal fillers, ECM-based injectables for skin regeneration (CellREDM), and premium dermocosmetics (BYRYZN BR). The company sells these products globally to healthcare professionals and aesthetic clinics across the U.S., China, Europe, Brazil, the Middle East, and other markets.

Product overview

Hugel is a South Korean medical aesthetics company offering a portfolio of botulinum toxin products (Letybo), dermal fillers, and ECM-based injectables (CellREDM). The company also expanded into premium dermocosmetics with the BYRYZN BR brand. Hugel's products are distributed globally across the U.S., China, Europe, and other markets, with the company targeting KRW900 billion in annual sales by 2028.

Differentiator

Problem solved

Functional benefit

Brands

• Letybo (letibotulinumtoxinA): FDA-approved botulinum toxin product for treating glabellar lines
• BYRYZN BR
• CellREDM

Products and services

• Letybo (letibotulinumtoxinA) FDA-approved botulinum toxin product for treating glabellar lines (frown lines). Sold to medical aesthetic practitioners and clinics as a competitively priced neuromodulator.
• Dermal Fillers Hugel's dermal filler products for facial aesthetics procedures, contributing to overseas sales growth alongside botulinum toxin products. Sold to aesthetic clinics and practitioners.
• CellREDM ECM (extracellular matrix)-based injectable product for skin regeneration treatments. Distributed in South Korea through partnership with Hans Biomed.
• BYRYZN BR (incl. Botuligin Capture EX Ampoule) Premium dermocosmetics brand launched in China for the high-end skin care market, starting with the Botuligin Capture EX Ampoule for anti-aging.

Quantifiable outcome

• 31+ million successful treatments recorded globally across 65 countries
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Hans BiomedcoreChannel Partner/ Reseller/ Distributor · 31 March 2026Hugel secured domestic sales rights for CellREDM and formed a distribution partnership with Hans Biomed in South Korea. The collaboration aims to enhance Hugel's aesthetic product portfolio and leverage synergies with existing offerings, targeting accelerated market penetration into ECM-based injectable market.
• BENEV Company, Inc.coreChannel Partner/ Reseller/ Distributor · 25 March 2025BENEV Company and Hugel announced full U.S. commercialization of Letybo through their partnership. Letybo became only the 6th neuromodulator to receive FDA approval in over 20 years, with over 31 million successful treatments recorded globally across 65 countries. The collaboration leverages BENEV's U.S. market presence and Hugel's position as the only South Korean company with regulatory approvals in the three largest botulinum toxin markets.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hugel Control